Neuroendocrine Neoplasms (NENs)

[1]  M. Neary,et al.  Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[2]  J. Zhao,et al.  Expression of PTEN and mTOR in pancreatic neuroendocrine tumors , 2013, Tumor Biology.

[3]  M. Al-Haddad,et al.  EUS for pancreatic neuroendocrine tumors: a single-center, 11-year experience. , 2010, Gastrointestinal endoscopy.

[4]  A. Nicholson,et al.  Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  D. Planchard,et al.  Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors. , 2016, Lung cancer.

[6]  W. Travis,et al.  Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  E. Speel,et al.  Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. , 2014, Gastroenterology.

[8]  I. Modlin,et al.  Current status of gastrointestinal carcinoids. , 2005, Gastroenterology.

[9]  E. D. de Vries,et al.  EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. , 2015, Gastrointestinal endoscopy.

[10]  I. Catalá,et al.  Definitive diagnosis of neuroendocrine tumors using fine-needle aspiration-puncture guided by endoscopic ultrasonography. , 2011, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[11]  K. S. Lee,et al.  Large Cell Neuroendocrine Carcinoma of the Lung: Clinical, CT, and Pathologic Findings in 11 Patients , 2001, Journal of thoracic imaging.

[12]  K. Klose,et al.  Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  G. Veronesi,et al.  Risk factors for complications of CT-guided lung biopsies , 2011, La radiologia medica.

[14]  M. Guimarães,et al.  CT-guided cutting needle biopsy of lung lesions--an effective procedure for adequate material and specific diagnose. , 2011, European journal of radiology.

[15]  R. Jensen,et al.  Gastroenteropancreatic neuroendocrine tumours. , 2008, The Lancet. Oncology.

[16]  N. Fazio,et al.  Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. , 2016, Cancer treatment reviews.

[17]  R. Jensen,et al.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors , 2016, Neuroendocrinology.

[18]  R. Semelka,et al.  MRI of carcinoid tumors: Spectrum of appearances in the gastrointestinal tract and liver , 2001, Journal of magnetic resonance imaging : JMRI.

[19]  Eric J. W. Visser,et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  P. Ruszniewski,et al.  ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms , 2016, Neuroendocrinology.

[21]  P. Ruszniewski,et al.  Lanreotide in metastatic enteropancreatic neuroendocrine tumors. , 2014, The New England journal of medicine.

[22]  H. Ueno,et al.  Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. , 2010, Japanese journal of clinical oncology.

[23]  S. Dosso,et al.  Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? , 2007, Cancer Chemotherapy and Pharmacology.

[24]  D. Radice,et al.  Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors , 2016, Neuroendocrinology.

[25]  J. Rehfeld,et al.  Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors , 2013, Scandinavian Journal of Gastroenterology.

[26]  J. Heymach,et al.  Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours , 2015, British Journal of Cancer.

[27]  K. Busam,et al.  The NF1 gene in tumor syndromes and melanoma , 2017, Laboratory Investigation.

[28]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[29]  E. Baudin,et al.  Prospective Endoscopic Ultrasonographic Evaluation of the Frequency of Nonfunctioning Pancreaticoduodenal Endocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1 , 2006, The American Journal of Gastroenterology.

[30]  E. Seregni,et al.  Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors , 1999, Cancer.

[31]  S. Michopoulou,et al.  The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom , 2016, The Journal of Nuclear Medicine.

[32]  K. Brown,et al.  Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. , 1999, Journal of vascular and interventional radiology : JVIR.

[33]  Zijie Feng,et al.  Epigenetic regulation by the menin pathway. , 2017, Endocrine-related cancer.

[34]  James C Yao,et al.  Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study , 2016, The Lancet.

[35]  V. Vilgrain,et al.  Liver transarterial embolizations in metastatic neuroendocrine tumors , 2017, Reviews in Endocrine and Metabolic Disorders.

[36]  G. Pelosi,et al.  Typical and Atypical Pulmonary Carcinoid Tumor Overdiagnosed as Small-Cell Carcinoma on Biopsy Specimens: A Major Pitfall in the Management of Lung Cancer Patients , 2005, The American journal of surgical pathology.

[37]  Hirotoshi Kikuchi,et al.  Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. , 2008, Endocrine-related cancer.

[38]  E. Krenning,et al.  ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas) , 2016, Neuroendocrinology.

[39]  E. Krenning,et al.  ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site , 2016, Neuroendocrinology.

[40]  R. Semelka,et al.  MRI of pancreatic tumors , 1997, European Radiology.

[41]  P. Björklund,et al.  Treatment, prognostic markers and survival in thymic neuroendocrine tumours. a study from a single tertiary referral centre. , 2013, Lung cancer.

[42]  V. Ambrosini,et al.  68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients , 2017, The Journal of Nuclear Medicine.

[43]  A. Sundin.  Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. , 2012, Best practice & research. Clinical gastroenterology.

[44]  A. Russo,et al.  Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential , 2018, Expert review of gastroenterology & hepatology.

[45]  L. Mariani,et al.  5‐fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors , 1998, Cancer.

[46]  M. Kaushik,et al.  A Review of Von Hippel-Lindau Syndrome , 2017, Journal of kidney cancer and VHL.

[47]  Peter Schirmacher,et al.  The 2019 WHO classification of tumours of the digestive system , 2019, Histopathology.

[48]  J. Crowley,et al.  Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007 , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[49]  J. Gong,et al.  Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas , 2013, Medical Oncology.

[50]  G. Sassolas,et al.  Interest of Chromogranin A for diagnosis and follow‐up of endocrine tumours , 2004, Clinical endocrinology.

[51]  M. Milas,et al.  Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. , 2007, Surgery.

[52]  I. Modlin,et al.  Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease , 2010, Annals of Surgical Oncology.

[53]  E. Baudin,et al.  Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. , 2017, The Lancet. Oncology.

[54]  M. Gambello,et al.  Molecular Genetic Basis of Tuberous Sclerosis Complex: From Bench to Bedside , 2004, Journal of child neurology.

[55]  T. de Baère,et al.  MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. , 2003, AJR. American journal of roentgenology.

[56]  Jie Chen,et al.  Chromogranin A as a Marker for Diagnosis, Treatment, and Survival in Patients With Gastroenteropancreatic Neuroendocrine Neoplasm , 2014, Medicine.

[57]  R. Semelka,et al.  Neuroendocrine tumors of the pancreas: Spectrum of appearances on MRI , 2000, Journal of magnetic resonance imaging : JMRI.

[58]  G. Casazza,et al.  Chromogranin A in Diagnosing and Monitoring Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Large Series from a Single Institution , 2014, Neuroendocrinology.

[59]  H. Sorbye,et al.  Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases , 2018, Cancer.

[60]  F. Pilleul,et al.  Hepatic Arterial Embolization versus Chemoembolization in the Treatment of Liver Metastases from Well-Differentiated Midgut Endocrine Tumors: A Prospective Randomized Study , 2012, Neuroendocrinology.

[61]  D. Planchard,et al.  Are G3 ENETS neuroendocrine neoplasms heterogeneous? , 2013, Endocrine-related cancer.

[62]  W. Oyen,et al.  Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[63]  I. Modlin,et al.  Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms , 2016, Nature Reviews Clinical Oncology.

[64]  F. D. De Braud,et al.  Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. , 2007, Endocrine-related cancer.

[65]  Jiaqian Wang,et al.  Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1 , 2013, Nature Communications.

[66]  J. Ajani,et al.  Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. , 1988, Annals of internal medicine.

[67]  J. Ramage,et al.  A Multimodal Approach to the Management of Neuroendocrine Tumour Liver Metastases , 2012, International journal of hepatology.

[68]  Shouhao Zhou,et al.  Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States , 2017, JAMA oncology.

[69]  C. Schade-Brittinger,et al.  Placebo-Controlled , Double-Blind , Prospective , Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors : A Report From the PROMID Study Group , 2009 .

[70]  W. Chung,et al.  Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  G. Kaltsas,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations , 2008, Neuroendocrinology.

[72]  K. Yasufuku,et al.  How I Do It—Optimal Methodology for Multidirectional Analysis of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[73]  R. Salem,et al.  Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies. , 2016, Surgery.

[74]  E. Baudin,et al.  Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  J R Galvin,et al.  Thoracic carcinoids: radiologic-pathologic correlation. , 1999, Radiographics : a review publication of the Radiological Society of North America, Inc.

[76]  K. Öberg.  Management of functional neuroendocrine tumors of the pancreas. , 2018, Gland surgery.

[77]  M. Fujishima,et al.  Carcinoid Tumors of the Duodenum: Report of Three Cases Treated by Endoscopic Resection , 1997, Endoscopy.

[78]  J. Berlin,et al.  Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.

[79]  I. Kayani,et al.  The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy , 2010, Journal of Nuclear Medicine.

[80]  G. Corradi,et al.  68Ga-DOTATATE PET/CT, 99mTc-HYNIC-Octreotide SPECT/CT, and Whole-Body MR Imaging in Detection of Neuroendocrine Tumors: A Prospective Trial , 2014, The Journal of Nuclear Medicine.

[81]  E. Van Cutsem,et al.  Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: RADIANT‐4 lung subgroup analysis , 2017, Cancer science.

[82]  D. Conte,et al.  Endoscopic techniques to detect small-bowel neuroendocrine tumors: A literature review , 2017, United European gastroenterology journal.

[83]  J. Ajani,et al.  The carcinoid syndrome: palliation by hepatic artery embolization. , 1986, AJR. American journal of roentgenology.

[84]  Laura H. Tang,et al.  Small-cell carcinomas of the gastrointestinal tract: a review. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  I. Floriani,et al.  Staging of colorectal liver metastases after preoperative chemotherapy. Diffusion-weighted imaging in combination with Gd-EOB-DTPA MRI sequences increases sensitivity and diagnostic accuracy , 2013, European Radiology.

[86]  C. Chougnet,et al.  Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. , 2015, Endocrine-related cancer.

[87]  H. Sorbye,et al.  Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3) , 2018, Medical Oncology.

[88]  M. Ducreux,et al.  Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin , 1999, British Journal of Cancer.

[89]  B. Skogseid,et al.  Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors , 1998, Cancer.

[90]  M. Fjällskog,et al.  Treatment with cisplatin and etoposide in patients with neuroendocrine tumors , 2001, Cancer.

[91]  H. Sorbye,et al.  Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[92]  P. Ruszniewski,et al.  Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. , 2016, The oncologist.

[93]  D. Santini,et al.  Autoimmune Pancreatitis Associated with High Levels of Chromogranin A, Serotonin and 5-Hydroxyindoleacetic Acid , 2008, Case Reports in Gastroenterology.

[94]  M. Kusumoto,et al.  CT findings of surgically resected large cell neuroendocrine carcinoma of the lung in 38 patients. , 2004, AJR. American journal of roentgenology.

[95]  K. Hirabayashi,et al.  Nonfunctioning pancreatic endocrine tumor with extension into the main pancreatic duct: Report of a case , 2011, Surgery Today.

[96]  I. Modlin,et al.  Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy. , 2015, The Journal of clinical endocrinology and metabolism.

[97]  P. Ruszniewski,et al.  Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. , 2005, Best practice & research. Clinical gastroenterology.

[98]  P. Castaldi,et al.  Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis , 2012, Endocrine.

[99]  R. Buchert,et al.  Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[100]  A. Rossi,et al.  Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  I. Modlin,et al.  Chromogranin A: any relevance in neuroendocrine tumors? , 2016, Current opinion in endocrinology, diabetes, and obesity.

[102]  W. Travis,et al.  Ki-67 Antigen in Lung Neuroendocrine Tumors: Unraveling a Role in Clinical Practice , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[103]  V. Hervieu,et al.  Gemcitabine and oxaliplatin combination chemotherapy for metastatic well‐differentiated neuroendocrine carcinomas , 2009, Cancer.

[104]  S. Agarwal.  The future: genetics advances in MEN1 therapeutic approaches and management strategies. , 2017, Endocrine-related cancer.

[105]  W. Weichert,et al.  mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. , 2011, Endocrine-related cancer.

[106]  L. Antonuzzo,et al.  Everolimus in Pancreatic Neuroendocrine Carcinomas G3 , 2017, Pancreas.

[107]  I. Drozdov,et al.  Gene network-based analysis identifies two potential subtypes of small intestinal neuroendocrine tumors , 2014, BMC Genomics.

[108]  G. Nikou,et al.  Chromogranin A Levels in Diagnosis, Treatment and Follow-Up of 42 Patients with Non-Functioning Pancreatic Endocrine Tumours , 2008, Pancreatology.

[109]  L. Kvols,et al.  Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms , 1991, Cancer.

[110]  F. Pilleul,et al.  Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors. , 2010, Clinical colorectal cancer.

[111]  Shouhao Zhou,et al.  Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. , 2017, The Lancet. Oncology.

[112]  R. Riechelmann,et al.  Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors , 2013, Rare tumors.

[113]  Jeffrey W. Clark,et al.  O-Methylguanine DNA Methyltransferase Deficiency and Response toTemozolomide-BasedTherapy in Patients with Neuroendocrine Tumors , 2008 .

[114]  A. Fernández-Villar,et al.  Effectiveness and safety of endobronchial ultrasound–transbronchial needle aspiration: a systematic review , 2009, European Respiratory Journal.

[115]  A. Vanoli,et al.  The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories , 2016, Neuroendocrinology.

[116]  V. Marotta,et al.  Limitations of Chromogranin A in clinical practice , 2012, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[117]  P. Niccoli,et al.  Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer , 2016, Molecular and clinical oncology.

[118]  D. Addrizzo-Harris,et al.  Executive Summary: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[119]  V. Hervieu,et al.  Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice , 2015, Cancer.

[120]  D. Breen,et al.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) , 2005, Gut.

[121]  E. Krenning,et al.  ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum , 2016, Neuroendocrinology.

[122]  L. Breimer,et al.  Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis , 2013, European Journal of Nuclear Medicine and Molecular Imaging.